openPR Logo
Press release

Biological Autoimmune Therapeutics Continue to Grow as Patients and Caregivers Seek Better Outcomes

11-08-2018 08:42 AM CET | Health & Medicine

Press release from: Greystone Research Associates

(Amherst, NH) – The administration of therapeutic immune modulators is becoming an increasingly important healthcare treatment option for a growing number of diseases and indications having broad implications for patient health and well-being. But to fully exploit the value of this class of therapeutics in both human and commercial terms, developers must successfully navigate the inherent limitations of drug storage and administration, moving away from infusion and toward injection as a route of administration.

Antibody drug products indicated for chronic conditions such as autoimmunity are often re-formulated, re-packaged and re-labeled into injectable form and re-introduced two to three years post-market launch to address the growing economic pressure and patient desire to avoid the need for out-patient infusion in favor of self-injection. There are several factors that are driving and influencing the market for autoimmune therapeutics.

Product Landscape

As more biosimilars enter the U.S. market, analysts expect to see U.S. price reductions similar to those that have occurred in Europe. However, of the seven biosimilars approved by FDA, sales of five biosimilars have been delayed by the actions of competitors. Three biosimilars (Erelzi, Amjevita, and Cyltezo) have had their marketing launch delayed by patent infringement lawsuits filed by brand-name manufacturers.

Biological Drug Supply Chain

During 2017, the biological drug supply chain experienced significant market consolidation as CMOs and CROs built out their scale and capability. A greater number of biologics manufacturers are seeking strategic partnerships while maintaining a global reach and access to the technologies they require. With this shift on the horizon, CMOs will find it necessary to enhance their capabilities in order to avoid account erosion.

As-supplied Packaging

As the administration of injectables moves increasingly from practitioner offices and healthcare facilities to patient homes, decisions regarding as-supplied packaging that were once considered boilerplate have moved to the early stages of the development process. A wide spectrum of device attributes, including form factor, device-patient interaction, security and safety, dosing, activation, off-device communication, and drug formulation factors have been incorporated into drug injection devices.

Self-Administration

The correlation between patient adherence and the benefits of self-administration continues to influence therapeutic product decisions, managed care initiatives and regulatory actions. For chronic conditions, adherence has a direct effect on the patient’s quality-of-life. Injectable devices with increased functionality and features address the natural desire of patients for simplicity and encourage enhanced adherence and appropriate behavior. New features that are increasingly being integrated into injection devices include dose memory, dose time stamping, selectable cartridge concentration and audible prompts.

Shared Decision Making

Readily accessible health information has led to a new class of patients - the informed patient. Informed patients are increasingly arriving for medical engagements armed with at least basic knowledge regarding their symptoms and/or condition. A growing number of informed patients expect to discuss their care and have some input into treatment decisions. This has led to a concept called Shared Decision Making (SDM). SDM is most effective when patients feel empowered by their ability to speak about health issues and medical history freely with their provider. The patient empowerment inherent in the SDM process reportedly has led to a reduction in patient stress and anxiety.


These developments are detailed in a new and comprehensive report researched and written by Greystone Research Associates. The report - Biological Autoimmune Therapeutics: Drugs, Devices, Packaging, Therapeutics & Forecasts analyzes autoimmune biologicals, how they’re administered and the way they’re packaged. The report includes analysis of competitive factors, therapeutic class product positioning, supply chain factors, device market share, and the product activities of sector participants.

More information is available at http://www.greystoneassociates.org

About Greystone

Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Contact:

Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
Voice: 603-595-4340
www.greystoneassociates.org

Source: Greystone Research Associates

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biological Autoimmune Therapeutics Continue to Grow as Patients and Caregivers Seek Better Outcomes here

News-ID: 1356439 • Views: 282

More Releases from Greystone Research Associates

Seeking to Capitalize on New Device Technology Drug Companies are Reformulating …
(Amherst, NH) – As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug product management. Much of the recent emphasis in this area has centered on efforts to extend patent rights protection. While reformulation has been and is an important approach, efforts to prolong IP benefits have only recently involved IV-to-SC drug re-engineering. This migration
Antibacterial Treatments that don’t Rely on Antibiotics Winding their way thro …
(Amherst, NH) – As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides. The quest to replace the current generation of antibiotics is complicated by the methods that bacteria have acquired to evade attempts to destroy them – methods often referred to a virulence factors. A microorganism can possess a wide array of virulence factors. They may only express these virulence factors when
3D Printing Positioned to Address Issues that have Prevented Wide Adoption of Mi …
(Amherst, NH) – The promise of commercial microneedle drug delivery has been on the horizon for more than a decade. Like other compelling medical device innovations such as noninvasive glucose monitoring, the potential of the technology has yet to be realized due to the inability to solve the issues of reliable product performance from unit to unit and across a wide user population. To fully address the unmet need these technologies
Analysis of the Oncology Drug Pipeline Reveals Evolving Therapy Correlations and …
(Amherst, NH) – The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from

All 5 Releases


More Releases for SDM

Global D-Biotin Market 2019 – Huge Market Growth Till 2024: Zhejiang Medicine, …
D-Biotin Market Biotin is a water-soluble B-vitamin, also called vitamin B7 and formerly known as vitamin H or coenzyme R. It is composed of a ureido ring fused with a tetrahydrothiophene ring. A valeric acid substituent is attached to one of the carbon atoms of the tetrahydrothiophene ring. Biotin is a coenzyme for carboxylase enzymes, involved in the synthesis of fatty acids, isoleucine, and valine, and in gluconeogenesis. More Insightful Information |
Biotin Market Is Booming Worldwide | Zhejiang Medicine, SDM, Hegno
HTF MI recently introduced Global Biotin Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are Zhejiang Medicine, SDM, Hegno, Shanghai Acebright, NUH, Anhui Tiger Biotech, Kexing Biochem
Global SDM Mast Foot Extensions Market Expected to Witness a Sustainable Growth …
New report published by Global Info Research which offers insights on the global SDM Mast Foot Extensions market. Click to view the full report TOC, figure and tables: https://www.globalinforesearch.com/global-sdm-mast-foot-extensions-market_p91332.html Global SDM Mast Foot Extensions Market: Forecast by Type / Application / Region The worldwide market for SDM Mast Foot Extensions is expected to grow at a CAGR of roughly x% over the next five years, will reach x million US$ in 2023, from x
Trending Top Opportunities for Subscriber Data Management (SDM) Market | Attract …
A new study titled, ‘Global Subscriber Data Management (SDM) Market’ added by Reports Monitor is a collection of different segmentations, which includes the product types and uses, foundation elements of (Subscriber Data Management (SDM)), and expected adoption timeline of Subscriber Data Management (SDM) in the industry. This report provides a detailed analysis of the various use cases and applications of Subscriber Data Management (SDM) in the ICT industry, their benefits,
Subscriber Data Management (SDM) Market - Global Industry Analysis, Size, Share, …
Global Subscriber Data Management (SDM) Industry New Study On “2018-2025 Subscriber Data Management (SDM) Market Global Key Player, Demand, Growth, Opportunities and Analysis Forecast” Added to Wise Guy Reports Database This report focuses on the global Subscriber Data Management (SDM) status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Subscriber Data Management (SDM) development in United States, Europe and China. Try Sample Report @ https://www.wiseguyreports.com/sample-request/3387717-global-subscriber-data-management-sdm-market-size-status-and-forecast-2018-2025 The
Global D-Biotin Market 2018 - DSM, NUH, BASF, SDM
The statistical surveying information incorporated into the D-Biotin report is the aftereffect of significant essential and optional research exercises. The report fragments the global D-Biotin market based on makers, item compose, applications, and regions. In this report, each fragment is contemplated completely and measurements are introduced in detail. The report offers an exact outline of the global D-Biotin advertise covering key factors, for example, drivers and restrictions affecting the development.